Women are less likely than men to receive drugs for multiple sclerosis (MS) between the ages of 18 to 40, during women's childbearing years, even when those drugs have been shown to be safe for use ...

Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million people estimated to be living with the disease worldwide. As MS is an ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

In multiple sclerosis (MS), a person's immune system attacks the protective covering (myelin sheath) of nerve fibers in the brain and spinal cord (central nervous system). MS disease-modifying ...

Effective management of multiple sclerosis (MS) relies heavily on sustained use of disease-modifying therapies (DMTs) to reduce relapse frequency, slow disability progression and preserve quality of ...

Prof Nicholas Schwab and his colleagues found a biomarker which allows to tell in advance if therapy with glatirameracetate will be efficient in an individual MS patent. Treatment with interferon or ...

Rituximab and ocrelizumab go head to head in randomized trial ...

People with multiple sclerosis appear to have higher rates of thyroid problems than the general population. The link isn’t clear, but shared pathways and MS medication side effects may play a role. MS ...

Rick Blum is meticulous about planning, ordering, and taking the medication he is prescribed to slow the progression of multiple sclerosis, a chronic and incurable neurological disorder that has ...